Neuroendocrine carcinomas, such as SCLC, express DLL3 in more than 85% of tumors [14], and in the digestive system, DLL3 is overexpressed in neuroendocrine carcinomas compared with neuroendocrine tumors [39]. This evidence concerns the gene DLL3 and neuroendocrine carcinoma.